CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma

NCT01806337 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
41
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

University of Göttingen